Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Entecavir (ETV) is a deoxyguanosine analog approved for use for the treatment of chronic infection with wild-type and lamivudine-resistant (LVDr) hepatitis B virus (HBV). In LVD-refractory patients, 1.0 mg ETV suppressed HBV DNA levels to below the level of detection by PCR (<300 copies/ml) in 21...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tenney, Daniel J., Rose, Ronald E., Baldick, Carl J., Levine, Steven M., Pokornowski, Kevin A., Walsh, Ann W., Fang, Jie, Yu, Cheng-Fang, Zhang, Sharon, Mazzucco, Charles E., Eggers, Betsy, Hsu, Mayla, Plym, Mary Jane, Poundstone, Patricia, Yang, Joanna, Colonno, Richard J.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2007
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1803124/
https://ncbi.nlm.nih.gov/pubmed/17178796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00833-06
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items